Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Fineline Cube Apr 14, 2026
Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Fineline Cube Apr 14, 2026
Company Deals

IASO Biotherapeutics Partners with Brazil’s Butantan Institute to Localize CAR-T Therapy for Hematological Cancers

Fineline Cube Apr 13, 2026
Company Deals

Zhejiang Medicine Plans HKEX Spin-Off of NovoCodex Biopharmaceuticals to Unlock ADC Pipeline Value

Fineline Cube Apr 13, 2026
Company Deals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

Fineline Cube Apr 13, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Fineline Cube Apr 14, 2026
Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Fineline Cube Apr 14, 2026
Company Deals

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

Fineline Cube Mar 20, 2024

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Policy / Regulatory

China Expands Medical Service Pricing Reform with Three Additional Pilot Provinces

Fineline Cube Mar 20, 2024

The National Healthcare Security Administration (NHSA) has announced an expansion of its medical services pricing...

Company

Swiss Pharma Firm Carbogen Amcis Receives Brazil’s ANVISA GMP Certification for Shanghai Site

Fineline Cube Mar 20, 2024

Carbogen Amcis, a Swiss firm specializing in active pharmaceutical ingredients (APIs) and pharmaceutical process development,...

Company

Everest Medicines Strengthens Leadership with Appointments of Sandra Zeng and Rico Liang

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a leading China-based biotechnology company, has announced two significant appointments to...

Company

WuXi XDC Breaks Ground on State-of-the-Art Manufacturing Base in Singapore to Boost ADC Production

Fineline Cube Mar 20, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Deals

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

Fineline Cube Mar 20, 2024

Shanghai Winpu Technology Co., Ltd., a specialist in medical-grade polymer materials based in China, has...

Company Drug

Everest Medicines’ Nefegan Approved by Singapore HSA for Primary IgAN Treatment

Fineline Cube Mar 20, 2024

Everest Medicines (HKG: 1952), a China-based biotechnology company, has received marketing approval from the Singapore...

Company

Shanghai Pharmaceuticals Appoints New Chairman Amid Leadership Shake-up

Fineline Cube Mar 20, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), one of the leading pharmaceutical giants in China,...

Company Deals

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Fineline Cube Mar 20, 2024

AstraZeneca (AZ; NASDAQ: AZN), the UK-based pharmaceutical giant, has announced its intention to acquire Fusion...

Company

China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements

Fineline Cube Mar 20, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...

Company Drug

Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin

Fineline Cube Mar 20, 2024

Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...

Company Drug

Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial

Fineline Cube Mar 20, 2024

Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...

Company Drug

China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis

Fineline Cube Mar 20, 2024

China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...

Company Drug

AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage...

Policy / Regulatory

China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal

Fineline Cube Mar 19, 2024

The National Joint Procurement Office in China has released a notification outlining the information and...

Company

WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles

Fineline Cube Mar 19, 2024

WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...

Company Drug

Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug...

Company Drug

Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...

Policy / Regulatory

CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations

Fineline Cube Mar 19, 2024

The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...

Company Drug

AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers

Fineline Cube Mar 19, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...

Posts pagination

1 … 371 372 373 … 650

Recent updates

  • Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M
  • Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration
  • Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History
  • Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years
  • AstraZeneca’s Imjudo Gains NMPA Approval for First-Line NSCLC in China, Backed by POSEIDON Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Harbin Gloria Pharmaceuticals Acquires Neurodegenerative Disease Candidate from Capital Medical University for RMB 14.15M

Company Deals

Menarini Group Partners with Shanghai Angel Baby Foundation on Three-Year Pediatric Scar Care Initiative – Dermatix Ultra Gel Expertise Extended to Public Welfare Collaboration

Company Drug

Eli Lilly’s Jaypirca Combination Therapy Demonstrates Significant PFS Benefit in Phase III CLL/SLL Trial – Non-Covalent BTK Inhibitor Shows Promise Regardless of Prior Treatment History

Company Drug

Sanofi Secures EC Approval for Dupixent in Pediatric Chronic Spontaneous Urticaria – First Biologic Therapy for Children 2–11 Years

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.